Cipaglucosidase Alfa + Miglustat
Phase 3Active 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pompe Disease (Late-onset)
Conditions
Pompe Disease (Late-onset)
Trial Timeline
Feb 13, 2020 → Jun 1, 2026
NCT ID
NCT03911505About Cipaglucosidase Alfa + Miglustat
Cipaglucosidase Alfa + Miglustat is a phase 3 stage product being developed by Amicus Therapeutics for Pompe Disease (Late-onset). The current trial status is active. This product is registered under clinical trial identifier NCT03911505. Target conditions include Pompe Disease (Late-onset).
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04808505 | Phase 3 | Recruiting |
| NCT03911505 | Phase 3 | Active |
Competing Products
20 competing products in Pompe Disease (Late-onset)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| S-606001 + Placebo | Shionogi | Phase 2 | 52 |
| alglucosidase alfa | Sanofi | Approved | 84 |
| GZ402666 | Sanofi | Phase 1 | 32 |
| alglucosidase alfa + Placebo | Sanofi | Phase 3 | 76 |
| alglucosidase alfa | Sanofi | Approved | 84 |
| glucosidase alfa | Sanofi | Pre-clinical | 22 |
| Alglucosidase alfa | Sanofi | Approved | 84 |
| Avalglucosidase Alfa | Sanofi | Phase 2 | 51 |
| alglucosidase alfa | Sanofi | Approved | 84 |
| Myozyme | Sanofi | Phase 3 | 76 |
| alglucosidase alfa | Sanofi | Approved | 84 |
| alglucosidase alfa | Sanofi | Pre-clinical | 22 |
| Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) | Sanofi | Phase 3 | 76 |
| Myozyme® (alglucosidase alfa) + Myozyme® (alglucosidase alfa) | Sanofi | Approved | 84 |
| ALGLUCOSIDASE ALFA | Sanofi | Approved | 84 |
| alglucosidase alfa + alglucosidase alfa | Sanofi | Approved | 84 |
| Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) | Sanofi | Phase 2 | 51 |
| Myozyme | Sanofi | Phase 2 | 51 |
| Myozyme | Sanofi | Phase 2 | 51 |
| recombinant human acid alpha-glucosidase (rhGAA) | Sanofi | Phase 2 | 51 |